Monday, October 27, 2014

Muscular Dystrophy Drug Suffers Setback

Sarepta Therapeutics said it would be delayed at least six months in seeking approval for its muscular-dystrophy drug after the FDA demanded more information because of concerns over the clinical-trial data.



from WSJ.com: US Business http://ift.tt/1wv5OB4

via IFTTT

No comments:

Post a Comment